AstraZeneca
Israeli-founded AI biotech Immunai expands AstraZeneca cancer collaboration
The expanded agreement extends and broadens the companies’ multi-year collaboration in oncology through 2027, according to the statement.
Immunai, AstraZeneca collaborate to optimize cancer clinical trials
US to move COVID-19 vaccines, treatments to private markets in 2023
AION, aMoon up for top scientific innovation award
Canada in talks to donate extra COVID-19 vaccines to poorer countries
The approach could undermine efforts to ensure vaccines are distributed fairly around the world, depending on whether certain funding and research goals are met.
AstraZeneca to move local headquarters to O-TECH complex
AstraZeneca will lease 1,245 sq.m. in Building B in the O-TECH complex.
AstraZeneca resumes US COVID-19 vaccine trial as J&J prepares to do same
AstraZeneca paused its US trial on Sept. 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial.
AstraZeneca resumes COVID-19 vaccine trial in Japan, US still paused
Trials in the UK, Brazil, South Africa and India had already restarted, but US trials remain paused.
AstraZeneca COVID-19 vaccine trial on hold after adverse patient reaction
The report said suspension of the trial was having an impact on other AstraZeneca vaccine trials - as well as on clinical trials being conducted by other vaccine makers.
Nine US, European COVID-19 vaccine developers sign pledge to uphold safety
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines.
Emergent signs deal to make British COVID-19 vaccine
AstraZeneca in June picked Emergent to help produce 300 million doses of its potential COVID-19 vaccine pledged to the United States.
AstraZeneca signs $6 bln cancer drug deal with Daiichi
The London-listed company said on Monday it would pay Daiichi an upfront payment of $1 billion for DS-1062, a type of antibody drug conjugate (ADC).
Moderna, Merck will not limit price of COVID-19 vaccines to company cost
Executives from Johnson & Johnson and AstraZeneca testified that they will price their respective potential vaccines at no profit while the pandemic rages on.